JAMA Medical News

Why Physicians Don't Deprescribe Medicines; What to Know About Wegovy's Rare but Serious Adverse Effects; What to Know About Zepbound, the Newest Antiobesity Drug Related Content: As Semaglutide's Popularity Soars, Rare but Serious Adverse Effects Are Emerging FDA Green-Lights Tirzepatide, Marketed as Zepbound, for Chronic Weight Management Deciding When It's Better to Deprescribe Medicines Than to Continue Them

JAMA Associate Editor Gregory Marcus, MD, a cardiologist and professor of medicine at the University of California San Francisco, speaks with American Heart Association Scientific Sessions 2023 conference chair Amit Khera, MD, MSc, a professor in the department of internal medicine at UT Southwestern Medical Center and the director of preventive cardiology. Related Content: Highlights From AHA 2023—New Risk Calculator, Semaglutide and CVD, and More

Nigam Shah, Stanford University professor, discusses reshaping medicine with AI. Topics include challenges with Electronic Health Records, training AI models with unbiased data, ethical data contribution, and the impact of technology on healthcare delivery.

Col Heather Yun, cochair of IDWeek 2023, discusses new vaccines, artificial intelligence, and antimicrobial resistance during the infectious disease conference. Topics include the impact of war and climate change, AI's role in real-time tracking, and studies on antimicrobial treatments, viral outbreaks, and vaccines.

JAMA Associate Editor John M. Inadomi, MD, discusses clinical highlights from United European Gastroenterology (UEG) Week with UEG president Helena Cortez-Pinto, MD, PhD. Related Content: Highlights From Gastroenterology Week: New Crohn Disease Drug, Redefining Liver Disease, and More

Suchi Saria, an associate professor in computer science at Johns Hopkins, discusses how AI can streamline care, the challenges in healthcare AI integration, the importance of collaborative interdisciplinary teams, exploring the impact of predictive AI in healthcare beyond chatbot technology, and the necessity of guardrails and federal oversight in AI governance.

Discussing the FDA approval of Alzheimer's drug Lecanumab, its effectiveness, high cost, and Medicare coverage; Exploring sex differences in the drug's effectiveness and skepticism about its clinical benefit; Examining challenges in the nursing workforce, including burnout and understaffing; Connecting nurse burnout to blood supply shortages; Exploring the scientific process of making universal donor blood in the lab and the challenges ahead.

JAMA Editor in Chief and Harvard's dean for medical education discuss AI's impact on medical education, including interactive learning, AI tools like ChachiPT for clinical decision-making, and challenges in training faculty.

Dr. Andrew Bindman, CMO of Kaiser Permanente, discusses the impact of AI in healthcare, addressing equity, patient privacy, and social risk factors. The conversation explores the use of AI technologies in improving patient care, managing biases, and maximizing health outcomes by addressing social determinants. The discussion also emphasizes striking a balance between the promises and risks of AI in healthcare innovation, focusing on patient-centric practices and enhancing healthcare experiences.

Dr. Kedar S. Mate discusses AI's role in healthcare quality and equity. Topics include challenges in implementing evidence-based care, the evolution of the Institute for Healthcare Improvement, integrating equity and AI in healthcare systems, biases and risks of digital algorithms, and addressing bias in AI training data for equitable healthcare outcomes.